Spyre Therapeutics (SYRE) Q3 2026 earnings review
Spyre drops its arthritis program, but raises cash for skin trials
Spyre Therapeutics, a developer of long-acting antibodies for autoimmune disorders, abandoned its joint disease program while expanding its bowel and skin trials. Its antibody SPY072 failed across three arthritis studies, so Chief Executive Cameron Turtle shifted the drug into a painful skin condition called hidradenitis suppurativa and raised $396 million net in October to fund it. Meanwhile, research spending nearly doubled to $89 million as the company completed early ulcerative colitis testing and expanded its main combination trial.
| Pro forma cash and securities | $1.47B includes $396M net raised in October |
|---|---|
| Research and development expense | $89.2M +97% from a year ago |
| Operating cash outflow | $77.5M +109% from a year ago |
| Cash runway outlook | Unchanged into the second half of 2029 |
⚖️ Verdict: 🔴 Bearish
The story got worse because Spyre's first placebo-controlled trials failed in all three joint diseases, wiping out a major pillar of the pipeline. In ulcerative colitis, its third antibody, SPY003, also produced a 20% remission rate in open-label testing, half the rate of its first drug. On the positive side, rapid patient sign-ups allowed Spyre to enlarge its combination bowel study for a third-quarter 2027 readout, and the October stock sale pays for the new skin program.
The question now is whether combining these antibodies in bowel disease and repurposing SPY072 for skin disease can deliver where single drugs in joint disease fell short. Either the combinations beat single treatments in placebo-controlled testing, or SPY003's lower standalone remission rate drags down the pairs. Third-quarter 2027 data from Part B of the SKYLINE bowel trial will settle it.
🐂 Bull Case
October Stock Sale Raised $396 Million Net
Spyre develops long-acting antibodies for autoimmune diseases and has no products on the market yet, so it funds clinical trials by selling stock. In October, after the third quarter closed, the biotechnology group raised $378 million in net proceeds from a public stock offering and another $18 million through an at-the-market share sale program.
Adding that $396 million by our math to the $1.07 billion on hand at the end of September brings pro forma cash and marketable securities to $1.47 billion. Spyre said the new money will "fund a pivotal program in HS with SPY072, our potential best-in-class TL1A monotherapy", giving it the capital to run late-stage skin studies alongside its bowel trials.
What to watch: the fourth-quarter common share count when full-year results arrive in early 2027. A large jump in shares will show how much ownership existing holders gave up to pay for the new skin disease trials.
Skin Disease Pivot Replaces the Joint Program
Rather than retiring SPY072, its antibody that blocks an inflammatory protein called TL1A, after poor joint results, Spyre moved the drug into hidradenitis suppurativa (HS), a painful, scarring skin condition. Chief executive Cameron Turtle cited "excellent external proof-of-concept data for TL1A in hidradenitis suppurativa" as the reason for the move into a market the company estimates affects 3 million Americans.
In September, the Massachusetts drug developer started the Phase 2 SKYLIGHT trial, giving SPY072 to patients who are also starting bimekizumab, an existing skin treatment. This study tests whether blocking two inflammatory pathways at once works before Spyre advances its own combined drug, SPY772, while management also plans to start a late-stage trial of SPY072 alone in HS in 2027.
What to watch: the start of the late-stage HS monotherapy trial in 2027 and initial 16-week SKYLIGHT combination data in late 2027 or early 2028. Delays in starting the late-stage study would leave Spyre without an active late-stage program for SPY072.
🐻 Bear Case
SPY072 Failed Across All Three Joint Diseases
Spyre tested SPY072 in the Phase 2 SKYWAY trial across three joint conditions: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), a form of spinal arthritis. Two quarters ago, the company planned to move SPY072 into late-stage development in 2027 if the rheumatoid arthritis results succeeded.
In August, the rheumatoid arthritis study beat placebo on symptom scores, but only "with a magnitude of benefit insufficient to prioritize advancement", Spyre said. The psoriatic arthritis and spinal arthritis studies then missed their main treatment goals at week 16, so management dropped SPY072 in all three rheumatic diseases and wrote off one of its two main disease areas from a year ago.
What to watch: any safety or dosing details from the closed SKYWAY trial that carry over to the new skin studies in 2027. If high doses still failed to clear inflammation in joints, SPY072 may face a high hurdle in severe skin disease.
SPY003 Showed Lower Remission Than Earlier Drugs
In September, Spyre reported Part A data from the Phase 2 SKYLINE trial in ulcerative colitis, an inflammatory bowel disease (IBD), for SPY003, an antibody targeting the IL-23 protein. "The combination portion of our SKYLINE trial is enrolling faster than expected enabling an increased enrollment target," chief executive Cameron Turtle said, setting Part B results for the third quarter of 2027.
- SPY001 (blocking the alpha-4-beta-7 protein): 40% clinical remission and 51% endoscopic improvement
- SPY002 (blocking the TL1A protein): 33% clinical remission and 42% endoscopic improvement
- SPY003 (blocking the IL-23 protein): 20% clinical remission and 30% endoscopic improvement
Turtle called all three single-drug readouts compelling, but SPY003 put half as many patients into remission as SPY001. Because two of the three combinations in Part B pair SPY003 with another antibody, a weaker standalone effect for SPY003 could limit how much it adds to those combinations.
What to watch: Part B combination induction results in the third quarter of 2027. If combinations containing SPY003 do not beat single drugs alone, Spyre's pairing thesis in bowel disease will weaken.
Clinical Trial Spending Nearly Doubled From 2025
Running multiple Phase 2 trials and manufacturing antibody combinations drove a sharp rise in costs during the third quarter. Research and development expenses climbed 97.1% from a year ago to $89.2 million, and rose 36.1% from the second quarter alone by our math.
Operating cash outflow more than doubled from a year ago to $77.5 million, up from $69.9 million in the second quarter. Even after raising $396 million net in October, Spyre kept its cash runway target at the second half of 2029, which by our math implies average quarterly cash burn will rise toward $122 million over the next 12 quarters as late-stage skin studies and larger bowel trials progress.
What to watch: quarterly operating cash outflow in the fourth-quarter report. A move above $90 million before the late-stage skin trial even begins would show that larger SKYLINE enrollment is consuming the October capital faster than planned.
💲 Other KPIs
Common shares used to calculate loss per share rose 46.3% from a year ago, following stock offerings in October 2025 and April 2026. This count does not yet include the shares sold in the October 2026 offering, which will lift the share count further in the fourth quarter.
Overhead and staffing costs increased 42.2% from a year ago and 2.6% from the second quarter. Management attributed the year-over-year increase to higher headcount and professional service fees as the company expands its clinical operations.
Contingent value rights (CVR) are milestone payment obligations tied to legacy drug assets. Total CVR liabilities dropped by $19.9 million since December 2025 by our math, with the short-term portion falling to zero in the third quarter after legacy milestones were settled earlier in the year.
🔮 Guidance
Unchanged. Spyre still expects its cash and marketable securities to fund operations into the second half of 2029, the same target it held in the first and second quarters. Holding the end date steady after adding $396 million in net October proceeds means the new late-stage skin trial and larger bowel study will absorb all of the extra cash over the next three years.
Unchanged. The company narrowed the readout window for its randomized combination bowel study to the third quarter of 2027, inside its prior full-year 2027 plan. Faster-than-expected patient enrollment allowed Spyre to increase the trial's size without pushing the results into 2028.
Unchanged on timing, but redirected to a new disease. Management still plans to start a late-stage study for SPY072 in 2027, shifting the drug into hidradenitis suppurativa after the rheumatoid arthritis trial failed to meet the bar for advancement.
New. Following the September start of the SKYLIGHT trial in hidradenitis suppurativa, Spyre expects 16-week proof-of-concept data in late 2027 or early 2028. The readout will determine whether the company moves its internal SPY772 combination antibody into advanced clinical trials.
❓ Key Questions
What were the exact remission numbers in the SKYWAY trials?
Spyre stated that SPY072 missed its primary goals in psoriatic and spinal arthritis and fell short of its internal bar in rheumatoid arthritis, but published no numeric response rates. Knowing how close the drug came to working in joints matters for judging its chances in skin disease.
How many patients did Spyre add to SKYLINE Part B?
Management raised the enrollment target for Part B of the SKYLINE ulcerative colitis trial because patients signed up ahead of schedule, yet did not disclose the old or new patient counts. The sample size determines how much statistical power the Q3 2027 combination readout will have.
How much will the new late-stage HS trial cost?
Spyre raised $396 million net in October to fund a pivotal SPY072 trial in hidradenitis suppurativa without extending its cash runway past the second half of 2029. Investors need to know how much of that raise goes to the skin trial versus the expanded bowel study.